Diagnosis and management of metastatic pancreatic tumors.
- Author:
Dong-kui XU
1
;
Ping ZHAO
;
Yong-fu SHAO
;
Cheng-feng WANG
;
Hong-wei LIN
;
Yan-tao TIAN
;
Yue-min SUN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Biopsy, Fine-Needle; Carcinoma, Small Cell; diagnosis; secondary; therapy; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; pathology; Magnetic Resonance Imaging; Male; Middle Aged; Pancreatic Neoplasms; diagnosis; secondary; therapy; Prognosis; Retrospective Studies; Stomach Neoplasms; pathology; Tomography, X-Ray Computed
- From: Chinese Journal of Oncology 2006;28(4):306-308
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinicopathological features and prognostic factors of metastatic pancreatic tumor.
METHODSThe clinical data of 18 metastatic pancreatic tumors were retrospectively analyzed. The primary foci of these 18 patients included: 8 lung cancer, 2 gastric cancer, and malignant histiocytoma, melanoma, rectal cancer, thyroid cancer, renal cell carcinoma, esophageal carcinoma, liver cancer and ovarian cancer each.
RESULTSAll these 18 patients harboring metastatic pancreatic tumor did not show any specific symptoms but were frequently found to have a solitary (14 cases) or multiple (4 cases) homogeneous and hypodense nodules on CT scan without any enhancement except one metastatic renal cell carcinoma. The diagnosis was cytologically confirmed in 14 patients by fine needle aspiration biopsy guided by CT or ultrasonography, and diagnosed by postoperative pathology in the other 4 patients. After receiving combined modality treatment, their survival time was 8 to 38 months with an average of 19 months.
CONCLUSIONMetastatic pancreatic tumors are rare and give no specific symptom or image finding. Selection of appropriate combined modality treatment according to the type of primary focus is very important for the management.
